Pharmacokinetics of oral busulphan in children with beta thalassaemia major undergoing allogeneic bone marrow transplantation

The pharmacokinetics of busulphan were studied in 23 thalassaemic children undergoing BMT. Patients received busulphan at a dose of either 16 mg/kg with cyclophosphamide and ATG (Group A) or 600 mg/m2 (with cyclophosphamide alone) (Group B) in 16 divided doses every 6 h over 4 days. Busulphan levels were analyzed by a modified GC-MS method. The dose of busulphan/kg for patients in group B was 64% (range 56-71%) higher than that for patients in group A. The mean AUC, Css, Cmax and MRV were significantly higher in group B as compared with group A for both doses 1 and 13. There was no significant difference in Vd/F, T1/2 and Kel between the two groups. A significant decrease in AUC and Css was found between 1st and 13th doses in group B, but not in group A. The Cl/F values in group A were significantly higher than those in group B after dose 1, but not after dose 13. No increase in toxicity due to the higher dose of busulphan was noted. We conclude that busulphan at 600 mg/m2 results in much higher systemic exposure to the drug as compared to 16 mg/kg, without increase in toxicity in children with beta thalassaemia major

Modeling and microstructural studies on anomalous electrodeposition of zinc-iron alloy

343-350This study correlates the deposition parameters with the alloy characteristics, through mathematical models based on zinc-iron alloy deposition. Both the partial and transition current densities have been determined. It should be noted that by designing specific models for a given boundary condition, the desired alloy composition can be achieved. The effect of deposition parameters on both cathodic as well as anodic potential and the electrochemical kinetics has also been investigated and the exchange current density values are computed. Effect of deposition rate as well as alloy phase composition over the textural characteristics and hkl planes is also observed

Evidence from UV Spectra for d-Orbital Utilization by Sulphur

388-39

Preliminary studies for a new antibiotic from the marine mollusk Melo melo (Lightfoot, 1786)

AbstractObjectiveTo search for new bioactive compounds from marine mollusks Melo melo (M. melo).MethodsPreliminary work for bioactive compound was identified by using disc diffusion methods against human pathogens. Further analyses of compound were done by using TLC, SDS-PAGE. And also estimate the amount of protein in the samples by following Biuret method.ResultsIn antibacterial activity the maximum diameter of 24 mm zone of inhibition was recorded against Klebsiella pneumoniae (K. pneumoniae) strain of the mucus extract and minimum zone of inhibition of 11 mm was observed in Salmonella typhi (S. typhi) strain of body tissue extract. The antifungal activity of the extraction shows maximum activity against Trichophyton mentagarophytes (T. mentagarophytes) (14 mm) and minimum activity was recorded in Aspergillus flavus (A. flavus) (11 mm). The extract of mucus, nerve tissue, body tissue and kidney that showed antimicrobial activity was subjected to TLC to determine the presence of the peptides and amide groups, and also subjected to SDS-PAGE to estimate the molecular weight of proteins in a clear band were detected in the gel that represented kidney, body tissue, brain and mucus represent 14, 17, 22, 45 kDa.ConclusionsThe extracts from marine mollusks M. melo is the potential source of producing bioactive compounds against human pathogens and can be used for synthesis of new drugs